Internal medicine, Leukemia, Gastroenterology, Surgery and Myeloid leukemia are his primary areas of study. His Internal medicine research integrates issues from Immunology and Oncology. His work in Oncology addresses subjects such as Survival analysis, which are connected to disciplines such as Salvage therapy.
He has researched Leukemia in several fields, including Myeloid and Pharmacology. His work deals with themes such as Cytarabine, Phases of clinical research, Blastic Phase and Survival rate, which intersect with Gastroenterology. His Myeloid leukemia study combines topics from a wide range of disciplines, such as Mutation, Fms-Like Tyrosine Kinase 3 and Young adult.
Guillermo Garcia-Manero mainly investigates Internal medicine, Oncology, Myeloid leukemia, Gastroenterology and Myelodysplastic syndromes. His Internal medicine research is multidisciplinary, incorporating perspectives in Surgery and Decitabine. Guillermo Garcia-Manero has included themes like Azacitidine, Cancer, Immunology and Transplantation in his Oncology study.
His work carried out in the field of Myeloid leukemia brings together such families of science as Tyrosine kinase and Bone marrow. The study incorporates disciplines such as Refractory, Imatinib mesylate, Vincristine, Adverse effect and Neutropenia in addition to Gastroenterology. The various areas that Guillermo Garcia-Manero examines in his Leukemia study include Myeloid and Pharmacology.
His primary areas of study are Internal medicine, Oncology, Myeloid leukemia, Cancer research and In patient. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Azacitidine. His studies in Oncology integrate themes in fields like Cytarabine, Decitabine, Venetoclax, Blinatumomab and Transplantation.
The Myeloid leukemia study combines topics in areas such as Hematopoietic stem cell transplantation, Chemotherapy regimen, Myeloid, Bone marrow and Cohort. His Myelodysplastic syndromes research includes elements of Lower risk, Clinical trial and Anemia. His research is interdisciplinary, bridging the disciplines of Cancer and Leukemia.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines for the use and interpretation of assays for monitoring autophagy
Daniel J. Klionsky;Fabio C. Abdalla;Hagai Abeliovich;Robert T. Abraham.
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg;Heinz Tuechler;Julie Schanz;Guillermo Sanz.
Clinical effect of point mutations in myelodysplastic syndromes.
Rafael Bejar;Kristen Stevenson;Omar Abdel-Wahab;Naomi Galili.
The New England Journal of Medicine (2011)
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Jean Pierre J. Issa;Guillermo Garcia-Manero;Francis J. Giles;Rajan Mannari.
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop Kantarjian;Yasuhiro Oki;Guillermo Garcia-Manero;Xuelin Huang.
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Omar Abdel-Wahab;Ann Mullally;Cyrus Hedvat;Guillermo Garcia-Manero.
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
Kathryn G. Roberts;Ryan D. Morin;Jinghui Zhang;Martin Hirst.
Cancer Cell (2012)
Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
Deborah A. Thomas;Stefan Faderl;Jorge Cortes;Susan O'Brien.
Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia
William Wierda;Susan O'Brien;Sijin Wen;Stefan Faderl.
Journal of Clinical Oncology (2005)
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
Deborah A. Thomas;Stefan Faderl;Susan O'Brien;Carlos Bueso-Ramos.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: